Other
Primary Ovarian Insufficiency
4
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Primary Ovarian Insufficiency is an early-stage landscape with 4 programs across 3 companies. The most active players are Eli Lilly, Novo Nordisk, Bayer. 1 therapy is approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Phase 31
Approved1
Analysis
Trial Status
3
clinical trials
Unknown status2 · 67%
Completed1 · 33%
Clinical Trials
Trial Activity
Primary Ovarian Insufficiency: Phenotype and Optimal Treatment
Completed·—·Phase 3·NCT03568708·19 enrolled
Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency
Unknown status·—·N/A·NCT05410093·150 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)